Cyclacel's CYC065 Featured in Presentations at the American Association for Cancer Research Annual Meeting 2015

Go back to Cyclacel's CYC065 Featured in Presentations at the American Association for Cancer Research Annual Meeting 2015

Cyclacel Pharma (CYCC) Tops Q4 EPS by 6c

March 24, 2015 4:18 PM EDT

Cyclacel Pharma (NASDAQ: CYCC) reported Q4 EPS of ($0.20), $0.06 better than the analyst estimate of ($0.26). Revenue for the quarter came in at $299 thousand, versus $247 thousand reported last year.

Cyclacel reported Q413 loss of $0.21 per share.

For earnings history and earnings-related data on Cyclacel Pharma (CYCC) click here.

... More